Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

SPECTRUM PHARMACEUTICALS, INC. (SPPI)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Spectrum Pharmaceuticals, Inc. : Hagens Berman Reminds Spectrum Pharmaceuticals Investors of May 13, 2013, Deadline in Securities Lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/03/2013 | 03:35pm CEST

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) investors of the May 13, 2013, lead plaintiff deadline in a pending lawsuit filed on their behalf. Investors who suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing [email protected].

The lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Investors who wish to move to be a lead plaintiff in the case may also contact the firm by calling (510) 725-3000 and must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at http://www.hb-securities.com/investigations/SPPI.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357
[email protected]


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPECTRUM PHARMACEUTICALS,
01:05pSPECTRUM PHARMACEUTICALS : Announces First Quarter 2018 Financial Results Teleco..
BU
04/24SPECTRUM PHARMACEUTICALS : Size, Structure Help Poziotinib Pose Threat to Deadly..
AQ
04/23SPECTRUM PHARMACEUTICALS : Announces Publication of Poziotinib Data in Nature Me..
BU
04/23SPECTRUM PHARMACEUTICALS : Highlights Data Showing Poziotinib Overcomes De Novo ..
AQ
04/17SPECTRUM PHARMACEUTICALS : Highlights Data Showing Poziotinib Overcomes De Novo ..
BU
04/16SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8..
AQ
04/13SPECTRUM PHARMACEUTICALS : Announces Update of MD Anderson's Phase 2 Data Studyi..
AQ
04/12SPECTRUM PHARMACEUTICALS, INC. : Wired News – Spectrum Pharma Reported Update Da..
AC
04/11SPECTRUM PHARMACEUTICALS : Down Following Positive Cancer Drug Test
AQ
04/11SPECTRUM PHARMACEUTICALS, INC. (NASD : SPPI) Is Running On Some Early Stage Data
AQ
More news
News from SeekingAlpha
04/24Looking For Action? S&P 1500 Most Volatile Stocks 
04/19DYNAVAX : Assessing The Underlying Fundamentals Of A Big Winner 
04/18SPECTRUM PHARMACEUTICALS : What To Expect From This Powerful Grower 
04/15PORTFOLIO REVIEW : Continued Market Outperformance In Q1 2018 
04/123 THINGS IN BIOTECH, APRIL 11 : Spectrum's Entree In EGFR, Karyopharm's Rush, On.. 
Financials ($)
Sales 2018 105 M
EBIT 2018 -111 M
Net income 2018 -122 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 16,9x
Capi. / Sales 2019 15,8x
Capitalization 1 781 M
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Technical analysis trends SPECTRUM PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 29,3 $
Spread / Average Target 72%
EPS Revisions
Managers
NameTitle
Joseph W. Turgeon President, Chief Executive Officer & Director
Stuart Mitchell Krassner Chairman
Thomas J. Riga Executive VP, Chief Operating & Commercial Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Guru Reddy Vice President-Preclinical Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICALS, INC.-10.24%1 781
CELLTRION, INC.--.--%29 110
IQVIA HOLDINGS INC-1.44%20 148
LONZA GROUP-9.23%18 502
NEKTAR THERAPEUTICS38.30%13 600
INCYTE CORPORATION-34.17%13 206